Effects of long-term administration of intranasal oxytocin on autism spectrum disorders

Not Applicable

• Conditions: Autism Pervasive developmental disorders

• Registration Number: JPRN-UMIN000009075
• Lead Sponsor: Osaka University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-11-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

We will exclude patients with cardio vascular disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The outcome measures are Abberant Behavior Checklist(ABC),Child Behavior Checklist(CBCL),Social Responsiveness Scale(SRS) completed by the caregivers and eye tracking tested before the administration of nasal oxytocin and at the end of each term(placebo or oxytocin). In addition,we will analyze mutations of CD38.

Secondary Outcome Measures

Name	Time	Method
The second outocome measures are blood pressure,urine osmolarity,urine sodium concentration and oxytocin concentration of his second urine in the morning.They are measured every time the participant comes to the hospital during the trial.